Abstract
The National Committee for Clinical Laboratory Standards (NCCLS) recommendations for screening and confirming the production of extended-spectrum beta-lactamases (ESBLs) were evaluated in 115 isolates of Escherichia coli and 157 isolates of Klebsiella spp. from Israeli patients with bacteremia. All isolates were screened using cefotaxime, ceftazidime, and cefpodoxime discs. Confirmatory tests using pairs of discs containing ceftazidime, cefotaxime, or cefpodoxime in which clavulanic acid was added to one of the discs in each pair [inhibitor-potentiated disc diffusion test (IPDDT)] and two double-sided E test strips containing ceftazidime or cefotaxime with and without clavulanic acid were performed on all isolates regardless of the results of screening tests. Isolates that tested positive by one or more confirmatory tests were considered ESBL producers. Overall, 69 (25.4%) strains were found to be ESBL producers. The sensitivity of the NCCLS screening criteria ranged between 98.6% for cefotaxime and 92.8% for ceftazidime, and the specificity ranged between 100% for cefotaxime and cefpodoxime and 99.0% for ceftazidime. The sensitivity of the confirmatory tests ranged between 97.1% for the cefotaxime E test and only 75.4% for the ceftazidime IPDDT discs. All 64 isolates that fell in the intermediate and resistant categories for cefotaxime, as well as all 41 in the same categories for ceftazidime and 68 of 69 in these categories for cefpodoxime, were confirmed as ESBL producers. The use of multiple antimicrobial discs for screening isolates and combinations of IPPDT discs is needed to improve the sensitivity of confirmatory testing. It is recommended that isolates falling in the intermediate and resistant categories in disc diffusion testing be reported as ESBL producers. The use of confirmatory tests should be limited to organisms with inhibition zone diameters ranging between the NCCLS recommendations for ESBL screening and the intermediate category breakpoints.
Similar content being viewed by others
References
Cormican MG, Marshall SA, Jones RN (1996) Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E test ESBL screen. J Clin Microbiol 34:1880–1884
Jacoby GA, Han P (1996) Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 34:908–911
Livermore DM, Brown DFJ (2001) Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 48 (Suppl S1):59–64
Vercautern E, Desheemaeker P, Ieven M, Sanders CC, Goossens H (1997) Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol 35:2191–2197
Essack SY (2000) Laboratory detection of extended-spectrum β-lactamases (ESBLs)—the need for a reliable, reproducible method. Diagn Microbiol Infect Dis 37:293–295
Canton R, Coque TM, Baquero F (2003) Multi-resistant gram-negative bacilli: from epidemics to endemics. Curr Opin Infect Dis 16:315–325
Paterson DL (2001) Extended-spectrum beta-lactamases: the European experience. Curr Opin Infect Dis 14:697–701
Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, Riesenberg K, Schlaeffer F (2001) Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 33:188–193
Bell JA, Turnidge JD, Gales AC, Pfaller MA, Jones RN, SENTRY APAC Study Group (2002) Prevalence of extended-spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia–Pacific region and South Africa; regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 42:193–198
Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO (2001) Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors and impact of resistance on outcomes. Clin Infect Dis 32:1162–1171
Carter MW, Oakton KJ, Warner M, Livermore DM (2000) Detection of extended-spectrum β-lactamases in klebsiellae with the Oxoid combination disk method. J Clin Microbiol 38:4228–4232
Emery CL, Weymouth L (1997) Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 35:2061–2067
National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S14. NCCLS, Wayne
Tenover FC, Mohammed J, Gorton TS, Dembek ZF (1999) Detection and reporting of organisms producing extended-spectrum β-lactamases: survey of laboratories in Connecticut. J Clin Microbiol 37:4065–4070
National Committee for Clinical Laboratory Standards (1997) Performance standards for antimicrobial disk susceptibility testing. Approved standard M2-A6. NCCLS, Wayne
National Committee for Clinical Laboratory Standards (1998) Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S8. NCCLS, Wayne
National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S9. NCCLS, Wayne
National Committee for Clinical Laboratory Standards (2001) Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S11. NCCLS, Wayne
National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing. Informational supplement M100-S12. NCCLS, Wayne
Bush K (2001) New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32:1085–1089
Gniadkowski M (2001) Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 7:597–608
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katz, O.T., Peled, N. & Yagupsky, P. Evaluation of the current National Committee for Clinical Laboratory Standards guidelines for screening and confirming extended-spectrum beta-lactamase production in isolates of Escherichia coli and Klebsiella species from bacteremic patients. Eur J Clin Microbiol Infect Dis 23, 813–817 (2004). https://doi.org/10.1007/s10096-004-1223-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-004-1223-4